DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

FDA Approves Injectable Form of Opdivo, Offering Greater Convenience for Cancer Patients

Reliance Acquires Oncology Platform Karkinos for ₹375 Crore

FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

Home
/
update
/
details

Caris Life Sciences Receives FDA Approval for Groundbreaking MI Cancer Seek™ Diagnostic Assay for Precision Oncology

NextEdge Admin

07 Nov 2024

1 min 48 sec

FDA,Precision Oncology,companion diagnostic

Caris Life Sciences® (Caris), a leader in AI-driven precision medicine, announced FDA approval of its MI Cancer Seek™ assay as a companion diagnostic (CDx) to guide treatment selection for cancer patients. MI Cancer Seek is the first FDA-approved CDx to use simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) for molecular profiling in solid tumors, covering one pan-cancer and five tumor-specific indications. It’s available for adults and pediatric patients (ages 1-22) and aligns with professional oncology guidelines.

This next-generation sequencing (NGS) in vitro diagnostic device analyzes total nucleic acid from formalin-fixed paraffin-embedded tumor tissue to detect 228 gene variants, microsatellite instability (MSI), tumor mutational burden (TMB), and copy number amplification in breast cancer cases. By identifying key biomarkers, MI Cancer Seek enables clinicians to match patients with targeted therapies, enhancing personalized treatment options.

Caris Chairman, Founder, and CEO David Dean Halbert expressed pride in bringing this groundbreaking tool to market, emphasizing the company’s commitment to advancing precision medicine. Caris President David Spetzler commended the FDA’s rigorous, collaborative review, which underscores the safety and efficacy of this novel diagnostic technology.